Opendata, web and dolomites

PureIgY SIGNED

Towards the use of IgY antibodies as alternative therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PureIgY" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDADE DE AVEIRO 

Organization address
address: CAMPUS UNIVERSITÁRIO DE SANTIAGO
city: AVEIRO
postcode: 3810-193
website: www.ua.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDADE DE AVEIRO PT (AVEIRO) coordinator 150˙000.00

Map

 Project objective

The increased occurrence of antibiotic-resistant pathogens is a critical concern corresponding to economic and societal challenges of high priority. Antimicrobial resistance (AMR) is responsible for 33,000 deaths per year, while bringing €1.5 billion per year in healthcare costs and productivity losses to the EU. Current solutions (biopharmaceuticals) are highly expensive and very few tackle the AMR scenario. Therefore, new approaches to tackling AMR focusing on low cost and relatively low time-to-market therapeutics must be pursued. Immunoglobulin Y (IgY) present in hen’s egg yolk is a potential alternative to the previously described biotherapeutics, and can be obtained in higher amounts from a renewable and non-invasive matrix. However, given the complex nature of egg yolk, the current purification technologies are multi-step and mainly based on chromatography, being highly expensive and leading to low yields. In the ERC Starting Grant (IgYPurTech) I proposed the use of aqueous biphasic systems (ABS) as IgY separation/purification platforms (from commercial and non-hyperimmune eggs since no therapeutic action was defined in the proposal). Although promising results have been obtained with ABS, during the IgYPurTech framework an additional and more cost-effective process to purify IgY was developed. It is not based on the selective extraction of antibodies for one of the phases in ABS, but on two steps of induced precipitation with appropriate salts and biopolymers. This innovative purification platform enables to produce high-quality IgY in higher amounts and at a significantly lower cost than other currently commercialized biotherapeutics. In this PoC Action – PureIgY – it is aimed to scale-up the developed purification technology, to address the biological features of specific IgY to tackle the AMR critical scenario, to work on the business plan development and business development, and to create an early-stage drug development start-up.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PUREIGY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PUREIGY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  

KEYNESGROWTH (2020)

Economic Fluctuations, Productivity Growth and Stabilization Policies: A Keynesian Growth Perspective

Read More